Calcium acetate with magnesium carbonate
Brand names: OsvaRen
Calcium acetate with magnesium carbonate is a combination oral phosphate binder used to treat hyperphosphataemia in adults with chronic kidney disease, especially dialysis patients.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Both calcium and magnesium salts bind dietary phosphate in the gut to form non-absorbable complexes, reducing phosphate absorption while lowering the overall calcium load compared with calcium-only binders.
Prescribing in practice
- Take with meals; the magnesium component can cause hypermagnesaemia and diarrhoea, so monitor magnesium and watch for loose stools in patients with reduced renal magnesium clearance.
- Combining calcium with magnesium reduces the elemental calcium dose for a given phosphate-binding effect, which may limit hypercalcaemia and calcium-related vascular calcification.
- Separate from oral iron, levothyroxine, bisphosphonates and certain antibiotics, whose absorption both cations reduce.
Monitoring
Monitor serum phosphate, calcium and magnesium regularly, adjusting the dose to control phosphate while avoiding hypercalcaemia or hypermagnesaemia.
Counselling the patient
- Take with food so it can bind the phosphate in your meal.
- Report persistent diarrhoea, muscle weakness or drowsiness, which may indicate high magnesium.
- Keep other calcium or magnesium-containing products separate unless advised.
Evidence & guidelines
Combined calcium-magnesium binders are an established phosphate-binding option in CKD-MBD management, offering effective phosphate control with a lower calcium burden than calcium-only binders.
Reference: NICE NG203; KDIGO; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019